Fiche publication
Date publication
juillet 2022
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONI Delphine
,
Pr FALCOZ Pierre-Emmanuel
,
Pr NOEL Georges
,
Dr SCHOTT Roland
,
Pr OLLAND Anne
,
Dr LE FEVRE Clara
Tous les auteurs :
Virbel G, Cox DG, Olland A, Falcoz PE, Le Fevre C, Schott R, Antoni D, Noel G
Lien Pubmed
Résumé
The oligometastatic stage is an intermediate stage of cancer between the localized stage and polymetastatic stage. The prognosis of patients in this stage also appears to be intermediate. Lung stereotactic body radiotherapy is a possible tool for treating oligometastatic lung sites. The objective of our study was to evaluate the clinical outcomes in terms of local control, progression-free survival, overall survival, and toxicity of SBRT in oligometastatic patients with lung metastases from any solid primary tumor.
Mots clés
SABR, SBRT, lung, metastases, oligometastatic, stereotactic body radiotherapy
Référence
Front Oncol. 2022 07 18;12:945189
